JW Therapeutics Announces IND Approval for the Clinical Trial of JWCAR129

SHANGHAI, Sept. 27, 2021 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, today announced that...

Full "IntellAsia: Resources" article